Skip to main content
Premium Trial:

Request an Annual Quote

Norwegian DNA Analysis Company iSentio Raises $1.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian DNA analysis company iSentio today announced it has raised $1.5 million to grow its sales and marketing efforts and accelerate development of new application areas for its RipSeq software.

The funding was led by existing and new investors, including Norwegian seed capital fund, Sarsia Seed, a new investor.

In a statement, the company said that it has had a successful market introduction of its web-based sequence RipSeq software for identifying multiple bacteria after direct sequencing of clinical patient samples. The software is used in hospitals in both Europe and the US.

The new funding was to done to capitalize on the momentum from the launch and will allow the company to expand its presence and address new markets, iSentio CEO Bjarte Karlsen said in a statement.

iSentio also named a new board chairperson, Siri Fürst, who has held various managerial positions at Hafslund, Hafslund Nycomed, and Nycomed Pharma. She was also CEO of DiaGenic.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.